Literature DB >> 10682669

Spontaneous apoptosis in ovarian carcinomas: a positive association with p53 gene mutation is dependent on growth fraction.

J Kupryjańczyk1, A Dansonka-Mieszkowska, T Szymańska, G Karpińska, A Rembiszewska, M Rusin, R Konopiński, E Kraszewska, A Timorek, D W Yandell, J Stelmachów.   

Abstract

Changes in cell survival contribute to tumour development, influence tumour biology and its response to chemotherapy. p53 gene alterations should negatively affect apoptosis by impaired p53-dependent apoptotic response. We looked for associations between spontaneous apoptosis, p53 gene mutation, p53 protein accumulation, growth fraction, bcl-2 expression and histological parameters in 64 ovarian, four tubal and three peritoneal carcinomas. Apoptotic cells were detected with the TUNEL method. p53 gene variants were detected by the single-strand conformation polymorphism and were sequenced directly. P53, Ki-67 and bcl-2 protein expressions were detected immunohistochemically. A weighed multiple logistic regression model was applied. Apoptotic index (AI) ranged 0.02-0.18 (mean 0.11); proliferation index (PI) ranged 3-90% (mean 54%). p53 gene mutations were present in 51, p53 protein accumulation in 46, and diffuse bcl-2 expression in 29 of 71 tumours. The AI was positively associated with the presence of p53 gene mutation (P = 0.011). However, the PI included into the analysis did positively influence the AI (P = 0.02) and diminished the association with p53 gene mutation (P = 0.082). The AI was negatively associated with good histological differentiation (P = 0.0006), the serous tumour type (P = 0.002), and diffuse bcl-2 expression (P = 0.025). Strong bcl-2 expression was associated with endometrioid tumour type (P = 0.002). FIGO stage and p53 protein accumulation were the only parameters that influenced overall survival time. Thus, our results suggest that histological tumour type and grade are major determinants of spontaneous apoptosis in ovarian carcinomas; p53 alterations do not adversely but rather positively affect spontaneous apoptosis by increasing growth fraction. This, in turn, suggests p53-independency of spontaneous apoptosis in ovarian carcinomas.

Entities:  

Mesh:

Year:  2000        PMID: 10682669      PMCID: PMC2363315          DOI: 10.1054/bjoc.1999.0967

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  29 in total

Review 1.  Roles for p53 in growth arrest and apoptosis: putting on the brakes after genotoxic stress.

Authors:  S A Amundson; T G Myers; A J Fornace
Journal:  Oncogene       Date:  1998-12-24       Impact factor: 9.867

2.  Histologic and nuclear grading and stromal reactions as indices for prognosis in ovarian cancer.

Authors:  H R Barber; S C Sommers; R Synder; T H Kwon
Journal:  Am J Obstet Gynecol       Date:  1975-03-15       Impact factor: 8.661

3.  Identification of a p53-dependent negative response element in the bcl-2 gene.

Authors:  T Miyashita; M Harigai; M Hanada; J C Reed
Journal:  Cancer Res       Date:  1994-06-15       Impact factor: 12.701

4.  p53-mediated cell death: relationship to cell cycle control.

Authors:  E Yonish-Rouach; D Grunwald; S Wilder; A Kimchi; E May; J J Lawrence; P May; M Oren
Journal:  Mol Cell Biol       Date:  1993-03       Impact factor: 4.272

5.  p53 and E2F-1 cooperate to mediate apoptosis.

Authors:  X Wu; A J Levine
Journal:  Proc Natl Acad Sci U S A       Date:  1994-04-26       Impact factor: 11.205

6.  Deregulated transcription factor E2F-1 expression leads to S-phase entry and p53-mediated apoptosis.

Authors:  X Q Qin; D M Livingston; W G Kaelin; P D Adams
Journal:  Proc Natl Acad Sci U S A       Date:  1994-11-08       Impact factor: 11.205

7.  Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo.

Authors:  T Miyashita; S Krajewski; M Krajewska; H G Wang; H K Lin; D A Liebermann; B Hoffman; J C Reed
Journal:  Oncogene       Date:  1994-06       Impact factor: 9.867

8.  p53-dependent apoptosis modulates the cytotoxicity of anticancer agents.

Authors:  S W Lowe; H E Ruley; T Jacks; D E Housman
Journal:  Cell       Date:  1993-09-24       Impact factor: 41.582

9.  p53 expression in epithelial ovarian neoplasms: relationship to clinical and pathological parameters, Ki-67 expression and flow cytometry.

Authors:  R Henriksen; P Strang; E Wilander; T Bäckström; B Tribukait; K Oberg
Journal:  Gynecol Oncol       Date:  1994-06       Impact factor: 5.482

10.  p53 gene mutations and protein accumulation in human ovarian cancer.

Authors:  J Kupryjańczyk; A D Thor; R Beauchamp; V Merritt; S M Edgerton; D A Bell; D W Yandell
Journal:  Proc Natl Acad Sci U S A       Date:  1993-06-01       Impact factor: 11.205

View more
  4 in total

1.  P53, bcl-2, ki-67 li (labeling index) status in benign, proliferative, and malignant ovarian surface epithelial neoplasms.

Authors:  Nesrin Gursan; Sare Sipal; Muhammed Calik; Cemal Gundogdu
Journal:  Eurasian J Med       Date:  2009-04

2.  Spontaneous and inducible apoptosis in oesophageal adenocarcinoma.

Authors:  A Raouf; D Evoy; E Carton; E Mulligan; M Griffin; E Sweeney; J V Reynolds
Journal:  Br J Cancer       Date:  2001-11-30       Impact factor: 7.640

3.  TP53 status determines clinical significance of ERBB2 expression in ovarian cancer.

Authors:  J Kupryjańczyk; R Madry; J Plisiecka-Hałasa; J Bar; E Kraszewska; I Ziółkowska; A Timorek; J Stelmachów; J Emerich; M Jedryka; A Płuzańska; I Rzepka-Górska; K Urbański; J Zieliński; J Markowska
Journal:  Br J Cancer       Date:  2004-11-29       Impact factor: 7.640

4.  Evaluation of clinical significance of TP53, BCL-2, BAX and MEK1 expression in 229 ovarian carcinomas treated with platinum-based regimen.

Authors:  J Kupryjańczyk; T Szymańska; R Madry; A Timorek; J Stelmachów; G Karpińska; A Rembiszewska; I Ziółkowska; E Kraszewska; J Debniak; J Emerich; M Ułańska; A Płuzańska; M Jedryka; M Goluda; A Chudecka-Głaz; I Rzepka-Górska; M Klimek; K Urbański; J Breborowicz; J Zieliński; J Markowska
Journal:  Br J Cancer       Date:  2003-03-24       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.